PF 5901

Drug Profile

PF 5901

Alternative Names: L 655238; REV 5901; Revlon 5901; RG 5901; RG 5901A

Latest Information Update: 09 Jan 2003

Price : $50

At a glance

  • Originator Purdue Frederick
  • Class Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists; Leukotriene C4 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Ocular inflammation

Most Recent Events

  • 09 Jan 2003 Discontinued - Clinical-Phase-Unknown for Asthma in USA (PO)
  • 09 Jan 2003 Discontinued - Preclinical for Ocular inflammation in USA (Ophthalmic)
  • 08 Jul 2002 No development reported - Clinical-Phase-Unknown for Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top